Profile of Prescription Medication in an Internal Medicine Ward
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Appendix A
Anatomical Main Group | Frequency | % N = 11,159 | |
---|---|---|---|
A | Alimentary Tract and Metabolism | 1901 | 17% |
B | Blood and Blood Forming Organs | 2606 | 23.4% |
C | Cardiovascular System | 2283 | 20.5% |
D | Dermatologicals | 28 | 0.3% |
G | Genito Urinary System and Sex Hormones | 144 | 1.3% |
H | Systemic Hormonal Preparations, excl. Sex Hormones and Insulins | 220 | 2.0% |
J | Anti-Infectives for Systemic Use | 1043 | 9.3% |
L | Antineoplastic and Immunomodulating Agents | 17 | 0.2% |
M | Musculo-Skeletal System | 151 | 1.4% |
N | Nervous System | 1913 | 17.1% |
P | Antiparasitic Products, Insecticides, and Repellents | 2 | 0% |
R | Respiratory System | 800 | 7.2% |
S | Sensory Organs | 27 | 0.2% |
V | Various | 24 | 0.2% |
References
- United Nations. World Population Ageing 2019 Highlights; United Nations: New York, NY, USA, 2019. [Google Scholar]
- Divo, M.J.; Martinez, C.H.; Mannino, D.M. Ageing and the epidemiology of multimorbidity. Eur. Respir. J. 2014, 44, 1055–1068. [Google Scholar] [CrossRef] [PubMed]
- Grina, D.; Briedis, V. The use of potentially inappropriate medications among the Lithuanian elderly according to Beers and EU (7)-PIM list—A nationwide cross-sectional study on reimbursement claims data. J. Clin. Pharm. Ther. 2017, 42, 195–200. [Google Scholar] [CrossRef] [PubMed]
- Stegemann, S.; Ecker, F.; Maio, M.; Kraahs, P.; Wohlfart, R.; Breitkreutz, J.; Zimmer, A.; Bar-Shalom, D.; Hettrich, P.; Broegmann, B. Geriatric drug therapy: Neglecting the inevitable majority. Ageing Res. Rev. 2010, 9, 384–398. [Google Scholar] [CrossRef]
- Martins, I.D.S. Deprescribing no idoso. Rev. Port. Clínica Geral 2013, 29, 66–69. [Google Scholar] [CrossRef]
- Lee, E.A.; Brettler, J.W.; Kanter, M.H.; Steinberg, S.G.; Khang, P.; Distasio, C.C.; Martin, J.; Dreskin, M.; Thompson, N.H.; Cotter, T.M.; et al. Refining the Definition of Polypharmacy and Its Link to Disability in Older Adults: Conceptualizing Necessary Polypharmacy, Unnecessary Polypharmacy, and Polypharmacy of Unclear Benefit. Perm. J. 2020, 24. [Google Scholar] [CrossRef]
- Davies, E.A.; O’Mahony, M.S. Adverse drug reactions in special populations—The elderly. Br. J. Clin. Pharm. 2015, 80, 796–807. [Google Scholar] [CrossRef] [PubMed]
- Gurwitz, J.H. Polypharmacy: A new paradigm for quality drug therapy in the elderly? Arch. Intern. Med. 2004, 164, 1957–1959. [Google Scholar] [CrossRef] [PubMed]
- Thake, M.; Lowry, A. A systematic review of trends in the selective exclusion of older participant from randomised clinical trials. Arch. Gerontol. Geriatr. 2017, 72, 99–102. [Google Scholar] [CrossRef] [PubMed]
- WHO Collaborating Centre for Drug Statistics Methodology—ATC/DDD. Available online: https://www.whocc.no/atc_ddd_index/ (accessed on 2 February 2021).
- Chocano-Bedoya, P.O.; Bischoff-Ferrari, H.A. DO-HEALTH: Vitamin D3-Omega-3-Home Exercise-Healthy Aging and Longevity Trial—Dietary Patterns in Five European Countries; Springer: Cham, Switzerland, 2019. [Google Scholar]
- Gutierrez Valencia, M.; Martinez Velilla, N.; Lacalle Fabo, E.; Beobide Telleria, I.; Larrayoz Sola, B.; Tosato, M. Interventions to optimize pharmacologic treatment in hospitalized older adults: A systematic review. Rev. Clin. Esp. 2016, 216, 205–221. [Google Scholar] [CrossRef] [PubMed]
- Abegaz, T.M.; Birru, E.M.; Mekonnen, G.B. Potentially inappropriate prescribing in Ethiopian geriatric patients hospitalized with cardiovascular disorders using START/STOPP criteria. PLoS ONE 2018, 13, e0195949. [Google Scholar] [CrossRef] [PubMed]
- Hernandez Martin, J.; Merino-sanjuán, V.; Peris-martí, J.; Correa-ballester, M.; Vial-escolano, R.; Merino-sanjuán, M. Applicability of the STOPP/START criteria to older polypathological patients in a long-term care hospital. Eur. J. Hosp. Pharm. 2018, 25, 310–316. [Google Scholar] [CrossRef] [PubMed]
- Renom-Guiteras, A.; Meyer, G.; Thurmann, P.A. The EU(7)-PIM list: A list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur. J. Clin. Pharm. 2015, 71, 861–875. [Google Scholar] [CrossRef]
- Fahrni, M.L.; Azmy, M.T.; Usir, E.; Aziz, N.A.; Hassan, Y. Inappropriate prescribing defined by STOPP and START criteria and its association with adverse drug events among hospitalized older patients: A multicentre, prospective study. PLoS ONE 2019, 14, e0219898. [Google Scholar] [CrossRef] [PubMed]
- O’Connor, M.N.; Gallagher, P.; Byrne, S.; O’Mahony, D. Adverse drug reactions in older patients during hospitalisation: Are they predictable? Age Ageing 2012, 41, 771–776. [Google Scholar] [CrossRef] [PubMed]
- Blanc, A.L.; Spasojevic, S.; Leszek, A.; Théodoloz, M.; Bonnabry, P.; Fumeaux, T.; Schaad, N. A comparison of two tools to screen potentially inappropriate medication in internal medicine patients. J. Clin. Pharm. Ther. 2018, 43, 232–239. [Google Scholar] [CrossRef] [PubMed]
- Ma, Z.; Zhang, C.; Cui, X.; Liu, L. Comparison of three criteria for potentially inappropriate medications in chinese older adults. Clin. Interv. Aging 2019, 14, 65–72. [Google Scholar] [CrossRef] [PubMed]
- Roller-Wirnsberger, R.; Thurner, B.; Pucher, C.; Lindner, S.; Wirnsberger, G.H. The clinical and therapeutic challenge of treating older patients in clinical practice. Br. J. Clin. Pharmacol. 2020, 86, 1904–1911. [Google Scholar] [CrossRef] [PubMed]
- Reeve, E.; Gnjidic, D.; Long, J.; Hilmer, S. A systematic review of the emerging definition of ‘deprescribing’with network analysis: Implications for future research and clinical practice. Br. J. Clin. Pharmacol. 2015, 80, 1254–1268. [Google Scholar] [CrossRef] [PubMed]
Study Population Characteristics | N = 616 |
---|---|
Age (years) | |
Median (Q1–Q3) | 85.0 (78.0–89.0) |
65–74 | 98 (15.9%) |
75–84 | 206 (33.4%) |
≥85 | 312 (50.7%) |
Gender | |
Female | 298 (48.4%) |
Male | 318 (51.6%) |
Hospitalization days | |
Median (Q1–Q3) | 12 (8–20) |
Range (minimum and maximum) | 4–90 |
No. of hospitalizations | |
1 hospitalization | 556 (90.2%) |
2 hospitalizations | 54 (8.8%) |
3 hospitalizations | 6 (1.0%) |
No. of prescribed medicines | |
Median (Q1–Q3) | 17 (13–22) |
Range (minimum and maximum) | 4–50 |
No. of simultaneous medicines prescribed per day | |
Median (Q1–Q3) | 12 (10–14) |
Range (minimum and maximum) | 3–27 |
ICD-10 diagnostics | N = 3873 |
A00-B99—Certain infectious and parasitic diseases | 96 (2.50%) |
C00-D49—Neoplasms | 79 (2.00%) |
D50-D89—Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | 220 (5.70%) |
E00-E89—Endocrine, nutritional and metabolic diseases | 636 (16.40%) |
F0-F99—Mental, Behavioral, and Neurodevelopmental disorders | 140 (3.60%) |
G00-G99—Diseases of the nervous system | 82 (2.10%) |
H00-H59—Diseases of the eye and adnexa | 11 (0.30%) |
H60-H95—Diseases of the ear and mastoid process | 14 (0.40%) |
I00-I99—Diseases of the circulatory system | 829(21.40%) |
J00-J99—Diseases of the respiratory system | 415 (10.70%) |
K00-K95—Diseases of the digestive system | 125 (3.20%) |
L00-L99—Diseases of the skin and subcutaneous tissue | 50 (1.30%) |
M00-M99—Diseases of the musculoskeletal system and connective tissue | 80 (2.10%) |
N00-N99—Diseases of the genitourinary system | 396 (10.20%) |
Q00-Q99—Congenital malformations, deformations, and chromosomal abnormalities | 1 (0.00%) |
R00-R99—Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified | 278 (7.20%) |
S00-T88—Injury, poisoning, and certain other consequences of external causes | 53 (1.40%) |
V00-Y99—External causes of morbidity | 32 (0.80%) |
Z00-Z99—Factors influencing health status and contact with health services | 336 (8.70%) |
Most Prescribed Medicines (3rd Level, Pharmacological Subgroup) | Frequency | % N = 11,159 |
---|---|---|
A02B—Drugs for Peptic Ulcer and Gastro-esophageal Reflux Disease (GORD) | 489 | 4.4% |
A06A—Drugs for Constipation | 381 | 3.4% |
A10A—Insulins and Analogues | 489 | 4.4% |
B01A—Antithrombotic Agents | 746 | 6.7% |
B05B—I.V. Solutions (I.V. solutions used in parenteral administration of fluids, electrolytes and nutrients) | 385 | 3.5% |
B05C—Irrigating Solutions (products used for bladder irrigation, surgical irrigation, incl. instruments) | 707 | 6.3% |
B05X—I.V. Solution Additives (I.V. solution additives are concentrated preparations containing substances used for correcting fluid and electrolyte balance and nutritional status) | 377 | 3.4% |
C03C—High-Ceiling Diuretics | 437 | 3.9% |
C07A—Beta Blocking Agents | 334 | 3.0% |
C09A—ACE Inhibitors | 723 | 6.5% |
J01C—Beta-Lactam Antibacterials, Penicillins | 356 | 3.2% |
N02B—Other Analgesics and Antipyretics | 739 | 6.6% |
N05A—Antipsychotics | 320 | 2.9% |
N05B—Anxiolytics | 298 | 2.7% |
R03A—Adrenergics, Inhalants | 314 | 2.8% |
Coefficient Value | p Value | ||
---|---|---|---|
Hospitalization days | R00-R99—Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified | 0.103 | 0.010 |
S00-T88—Injury, poisoning, and certain other consequences of external causes | 0.106 | 0.009 |
Coefficient Value | p Value | ||
---|---|---|---|
Age | A10A—Insulins and Analogues | −0.111 | 0.006 |
N05B—Anxiolytics | −0.110 | 0.006 | |
B05C—Irrigating Solutions (products used for bladder irrigation, surgical irrigation, incl. instruments | 0.165 | <0.0001 | |
C03C—High-Ceiling Diuretics | 0.171 | <0.0001 | |
J01C—Beta-Lactam Antibacterials. Penicillins | 0.119 | 0.003 | |
R03A—Adrenergics, Inhalants | 0.106 | 0.009 |
Coefficient Value | p Value | ||
---|---|---|---|
Hospitalization days | simultaneous medicines per day | 0.089 | 0.045 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Perpétuo, C.; Plácido, A.I.; Aperta, J.; Herdeiro, M.T.; Roque, F. Profile of Prescription Medication in an Internal Medicine Ward. Healthcare 2021, 9, 704. https://doi.org/10.3390/healthcare9060704
Perpétuo C, Plácido AI, Aperta J, Herdeiro MT, Roque F. Profile of Prescription Medication in an Internal Medicine Ward. Healthcare. 2021; 9(6):704. https://doi.org/10.3390/healthcare9060704
Chicago/Turabian StylePerpétuo, Carla, Ana I. Plácido, Jorge Aperta, Maria Teresa Herdeiro, and Fátima Roque. 2021. "Profile of Prescription Medication in an Internal Medicine Ward" Healthcare 9, no. 6: 704. https://doi.org/10.3390/healthcare9060704
APA StylePerpétuo, C., Plácido, A. I., Aperta, J., Herdeiro, M. T., & Roque, F. (2021). Profile of Prescription Medication in an Internal Medicine Ward. Healthcare, 9(6), 704. https://doi.org/10.3390/healthcare9060704